SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT01648998

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

The Effects of Fludrocortisone on Information Processing in Healthy Female Volunteers

Stimulating the mineralocorticoid receptor (MR) may restore a disturbed balance as seen in depression. In this double-blind, randomized, placebo-controlled trial the investigators will test the effects of a single dose (500mg) fludrocortisone, an MR-agonist, on the information processing in healthy female volunteers (N = 2x20). The investigators want to investigate whether the acute administration of fludrocortisone (FC) in healthy females enhances the appraisal of emotional information related to depression, hypothesizing that: - FC relative to placebo selectively improves the recognition of happy and fearful faces: resulting in more correct responses and faster RTs. - FC induces a bias towards more positive self-description and an improved memory for positive information. Female participants were selected because the haplotype MRI180V is related to depression vulnerability in women, not in men. If the effects of fludrocortisone are comparable to the effects of antidepressants on the same tests and the same population, it might be a first indication that fludrocortisone may function as an antidepressant.

NCT01648998 Depression
MeSH: Depression

2 Interventions

Name: Fludrocortisone

Description: single dose 500 mg, capsule

Type: Drug


Name: Placebo

Type: Drug


Primary Outcomes

Description: This primary outcome is measured by performing the Facial Expression Recognition Task (FERT).

Measure: Accuracy to recognize emotions in facial expressions

Time: 2 hrs after intake fludrocortisone or placebo

Description: This primary outcome is measured by the Emotional categorization and Memory(EMT)task. This task consists of two parts, the encoding and recall.

Measure: Explicit memory for positive and negative information

Time: 2 hrs after intake of fludrocortisone or placebo

Secondary Outcomes

Description: This is measured by administration of the 'Positive Affect Negative Affect Schedule'(PANAS). It measures positive and negative mood states (tension, vigor, anxiety, fatigue, boredom, alertness...) (20 items adding to two subscales, positive and negative affect).

Measure: Subjective mood states

Time: 2 hrs after intake fludrocortisone or placebo

Purpose: Treatment

Allocation: Randomized

Parallel Assignment

There is one SNP


1 I180V

This MR I180V gene variant showed less activity in vitro, which suggests that functionality in vivo is decreased. --- I180V ---

HPO Nodes